Publication | Closed Access

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

Hematological MalignancyChronic Myeloid LeukemiaOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyMyeloid NeoplasiaPharmacotherapyDeep Molecular ResponseMedicineRadiation OncologyCancer ResearchStandard DoseHealth Sciences